Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials

Gastrointestinal Endoscopy

Volumn 70, Issue 4, 2009, Pages

  Ravipati, Mamata ^a   Katragadda, Srikanth ^a   Swaminathan, Paari Dominic ^a   Molnar, Janos ^a   Zarling, Edwin ^a  

^a ST VINCENT MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NADOLOL; NITRATE; PROPRANOLOL; SUCRALFATE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG DOSE TITRATION; DRUG EFFICACY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES BLEEDING; HUMAN; META ANALYSIS; MORTALITY; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 70349322585     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2009.02.029     Document Type: Article

References (51)

1. Terblanche J., Burroughs A.K., and Hobbs K.E. Controversies in the management of bleeding esophageal varices. N Engl J Med 320 (1989) 1393-1398
2. Thompson A.B.R., and Shaffer E.A. First principles of gastroenterology. 3rd ed (2005), Canadian Association of Gastroenterology, Oakville, Ontario Chapter 5, p. 89
3. de Franchis R. Portal hypertension II. Proceedings of the Second International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies (1996), Blackwell Science Ltd, Oxford
4. Lowe R., and Grace N. Primary prophylaxis of variceal hemorrhage. Clin Liver Dis 5 (2001) 665-676
5. Mills P.R., Rae A.P., Farah D.A., et al. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 25 (1984) 73-78
6. Dawson J., Gertsch P., Moismann F., et al. Endoscopic variceal pressure measurements: response to isosorbide dinitrate. Gut 26 (1985) 843-847
7. Navasa M., Chesta J., Bosch J., et al. Reduction of portal pressure by isosorbide mononitrate in patients with cirrhosis, effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 96 (1989) 1110-1118
8. Moreau R., and Lebrec D. Nitrovasodilators and portal hypertension. J Hepatol 10 (1990) 263-267
9. Pagliaro L., Burroughs A.K., Sorense T.I.A., et al. Therapeutic controversies and randomized trials (RCTs): prevention of bleeding and re-bleeding in cirrhosis. Gastroenterol Int 2 (1989) 71-84
10. D'Amico G., Pagliaro L., and Bosch J. The treatment of portal hypertension: a meta-analytic view. Hepatology 22 (1995) 332-354
11. Bernard B., Lebrec D., Mathurin P., et al. Propranolol and sclerotherapy in the prevention of gastrointestinal re-bleeding in patients with cirrhosis: a meta-analysis. J Hepatol 26 (1997) 312-324
12. Maria M., Thalheimer U., and Burroughs A. Prevention of variceal re-bleeding. Medscape Gen Med 5 (2003) 278
13. Alexandrino P.T., Alves M.M., and Correia J.P. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding, a prospective randomized controlled trial. J Hepatol 7 (1988) 175-185
14. Dasarathy S., Dwivedi M., Bhargava K.D., et al. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) Cirrhotic patients. Hepatology 16 (1992) 89-94
15. Fleig W.E., Stange E.F., Hunecke R., et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 7 (1987) 355-361
16. Teres J., Bosch J., Bordas J., et al. Propranolol versus sclerotherapy in preventing variceal re-bleeding, a randomized controlled trial. Gastroenterology 105 (1993) 1508-1514
17. Rossi V., Cales P., Burtin P., et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients, a prospective controlled trial of propranolol and sclerotherapy. J Hepatol 12 (1991) 283-289
18. Villanueva C., Balanzo J., Novella M.T., et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal re-bleeding. N Engl J Med 334 (1996) 1624-1629
19. Westaby D., Polson R.J., Gimson A.E., et al. A randomized controlled trial of oral propranolol compared with injection sclerotherapy for the long term management of variceal bleeding. Hepatology 11 (1990) 353-359
20. Acharya S.K., Dasarathy S., Saksena S., et al. A prospective randomized study to evaluate propranolol in patients undergoing long term endoscopic sclerotherapy. J Hepatol 19 (1993) 291-300
21. Avegrinos A., Rekoumis G., and Klonis C. Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial. J Hepatol 19 (1993) 301-311
22. Bertoni G., Fornaciari G., Beltrami M., et al. Nadolol for prevention of variceal re-bleeding during the course of endoscopic injection sclerotherapy: a randomized pilot study. J Clin Gastroenterol 12 (1990) 364-365
23. Jensen L.S., and Krarup N. Propranolol in prevention of re-bleeding from oesophageal varices during the course of endoscopic sclerotherapy. Scand J Gastroenterol 24 (1989) 339-345
24. Gerunda G.E., Neri D., Zangrandi F., et al. Nadolol does not reduce early rebleeding in cirrhosis undergoing endoscopic variceal sclerotherapy: a multicenter randomized controlled trial. [abstract]. Hepatology 12 (1990) 988
25. Vickers C., Rhodes J., Chesner I., et al. Prevention of re-bleeding from esophageal varices, two year follow up of a prospective controlled trial of propranolol in addition to sclerotherapy. J Hepatol 21 (1994) 81-87
26. Vinel J.P., Lamouliatte H., Cales P., et al. Propranolol reduces the re-bleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology 102 (1992) 1760-1763
27. Westaby D., Melia W., Hegarty J., et al. Use of propranolol to reduce the re-bleeding rate during injection sclerotherapy prior to variceal obliteration. Hepatology 6 (1986) 673-675
28. Elsayed S.S., Shiha G., Hamid M., et al. Sclerotherapy versus sclerotherapy and propranolol in the prevention of re-bleeding from esophageal varices, a randomized study. Gut 38 (1996) 770-774
29. Lundell L., Leth R., Lind T., et al. Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions. Acta Chir Scand 156 (1990) 711-715
30. Dowidar N., Hafez A., and Abdel Baki M. Endoscopic sclerotherapy of oesophageal varices due to hepato-splenic schistosomiasis, a randomized controlled trial evaluating the effect of adjuvant propranolol therapy. J Egypt Soc Parasitol 35 (2005) 773-786
31. Lo G.H., Chein W.C., Chen M.S., et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal re-bleeding. Gastroenterology 123 (2002) 728-734
32. Villanueva C., Minana J., Ortiz J., et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 345 (2001) 647-655
33. Patch D., Sabin C.A., Goulis J., et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal re-bleeding in patients with cirrhosis. Gastroenterology 123 (2002) 1013-1019
34. Sarin S.K., Wadhawan M., Gupta R., et al. Evaluation of endoscopic variceal ligation (EVL) versus propranolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal re-bleeding. Comparison of cirrhotic and non-cirrhotic patients. Dig Dis Sci 50 (2005) 1538-1547
35. Lo G.H., Lai K.H., Cheng J.S., et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal re-bleeding: a prospective randomized trial. Hepatology 32 (2000) 461-465
36. de la Peña J., Brullet E., Sanchez-Hernandez E.S., et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding. A multicenter trial. Hepatology 41 (2005) 572-578
37. Jain A., Kumar A., Tyagi P., et al. Endoscopic variceal ligation (EVL) plus propranolol (P) and isosorbide mononitrate (ISMN) versus endoscopic variceal ligation alone in secondary prophylaxis of variceal bleeding. A prospective randomized controlled trial. Presented at American College of Gastroenterology (2006) October 20-25, 2006; Las Vegas, Nevada
38. Romero G., Kravetz D., Argonz J., et al. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal re-bleeding in cirrhotic patients. A randomized controlled trial. Aliment Pharmacol Ther 24 (2006) 601-611
39. Monitinho E., Escorsell A., Bandi J.C., et al. Prognostic value of early measurements of portal pressure, presence of gastroesophageal varices and variceal bleeding. Gastroenterology 117 (1999) 626-631
40. Infante-Rivard C., Esnaola S., and Villeneuve J.P. Role of endoscopic sclerotherapy in the long term management of variceal bleeding, a meta-analysis. Gastroenterology 96 (1989) 1087-1092
41. Lo G.H., Lai K.H., Cheng J.S., et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 25 (1997) 1101-1104
42. D'Amico G., and Luca A. Natural history clinical-hemodynamic correlations. Prediction of the risk of bleeding. Ballieres Clin Gastroenterol 11 (1997) 243-256
43. Jalan R., Forrest E.H., Stanley A.J., et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of re-bleeding from esophageal varices. Hepatology 26 (1997) 1115-1122
44. Lo G.H., Liang H.L., Lai K.H., et al. The impact of endoscopic variceal ligation on the pressure of the portal venous system. J Hepatol 24 (1995) 74-80
45. Lebrec D., Nouel O., Cobric M., et al. Propranolol-a medical treatment for hypertension?. Lancet 2 (1980) 180-182
46. Hosking S.W., Kennedy H.J., Seddon I., et al. The role of propranolol in congestive gastropathy of portal hypertension. Hepatology 7 (1987) 437-441
47. Jensen L.S., and Krarup N. Propranolol may prevent recurrence of esophageal varices after obliteration by endoscopic sclerotherapy. Scand J Gastroenterol 24 (1989) 339-345
48. Elsayed S.S., Shiha G., Hamid M., et al. Sclerotherapy versus sclerotherapy and propranolol in the prevention of re-bleeding from oesophageal varices, a randomized study. Gut 38 (1996) 770-774
49. Garcia Pagan J.C., Escorsell A., Monitinho E., et al. Influence of pharmacological agents on portal hemodynamics basis for its use in the treatment of portal hypertension. Semin Liver Dis 19 (1999) 427-438
50. Feu F., García Pagán J.C., Bosch J., et al. Relationship between portal pressure response pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 346 (1995) 1056-1059
51. Bosch J., Mastai R., Kravetz D., et al. Effects of propranolol on azygous venous blood flow and hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 4 (1984) 1200-1205